What could happen if OCI division of FDA were to investigate the facts falsification involved in the Hikma and Dr. Reddy joint strategy employed in their post-trial findings of fact and brief to invalidate 6 Amarin patents embracing the severe hypertriglyceride indication of use, and finds fraud on the Nevada District Court as well as the Federal Circuit Court of Appeals? In case you are wondering what I'm talking about, the facts and related law are set forth In the Amarin shareholder Petition for Writ of Certiorari filed in the Supreme Court in 2022.
Were FDA(OCI), FTC, DOJ(FBI) or SEC aware of those facts at the time FDA approved the respective labels Hikma and Dr. Reddy received to market and sell their products in the United States? Did those generic companies omit material facts relating to information they furnished to FDA, prior to FDA approval of those labels? All hypothetical so far...........?
Market Data 
Markets 
AI
